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Abstract: The thermodynamically unstable nature of amorphous drugs has led to a persistent stability
issue of amorphous solid dispersions (ASDs). Lately, microwave-induced in situ amorphization
has been proposed as a promising solution to this problem, where the originally loaded crystalline
drug is in situ amorphized within the final dosage form using a household microwave oven prior to
oral administration. In addition to circumventing issues with physical stability, it can also simplify
the problematic downstream processing of ASDs. In this review paper, we address the significance
of exploring and developing this novel technology with an emphasis on systemically reviewing
the currently available literature in this pharmaceutical arena and highlighting the underlying
mechanisms involved in inducing in situ amorphization. Specifically, in order to achieve a high drug
amorphicity, formulations should be composed of drugs with high solubility in polymers, as well
as polymers with high hygroscopicity and good post-plasticized flexibility of chains. Furthermore,
high microwave energy input is considered to be a desirable factor. Lastly, this review discusses
challenges in the development of this technology including chemical stability, selection criteria for
excipients and the dissolution performance of the microwave-induced ASDs.
Keywords: microwave irradiation; amorphous solid dispersions; poorly soluble drugs; in situ
amorphization; physical stability
1. Introduction
Oral administration is the most commonly used route of administration, offering various
advantages including convenience of administration, compliance of medication, safety and economy.
However, with the advent of combinatorial chemistry and high-throughput screening technology,
a significant number of bioactive lipophilic and hydrophobic compounds have been synthesized
but exhibit poor aqueous solubility and concomitantly poor oral bioavailability [1]. Currently, it is
estimated that about 90% of leading compounds in the drug discovery process, 75% of drug candidates
in the drug development process and 40% of the top 200 oral drugs in the US and European markets
are facing solubility challenges [2]. To alleviate the burden of drug discovery and development and
improve the clinical efficacy, more effective approaches are in urgent need of overcoming the solubility
issue of poorly soluble drugs.
Amorphous solid dispersions (ASDs), are a solid-state dispersion with an amorphous active
pharmaceutical ingredient (API) molecularly dispersed in pharmacologically inert carriers. ASDs are
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regarded as one of the most promising and efficient techniques for the solubilization of poorly water
soluble APIs [3,4]. ASDs have been widely studied, and there have been a huge number of high quality
reviews summarizing the development and research progress of ASDs [5–11]. Thus, this review only
provides a very brief introduction to ASDs, which leads to the main focus of the review, i.e., microwave
induced in situ amorphization, as an upcoming approach to solving the physical stability concerns
of ASDs.
As predicted by Hancock et al., amorphous APIs exhibited 10 to 1600 times higher solubility
than their most stable crystalline counterparts due to their higher Gibbs free energy [12]. However,
such difference in free energy is also regarded as a thermodynamic driving force for recrystallization [13].
ASDs can benefit from the solubility advantage of amorphous APIs and meanwhile enhance the stability
of amorphous drugs with the assistance of polymeric carriers, where polymers act as anti-plasticizers
and reduce the collisions between drug molecules and help with the supersaturation maintenance by
virtue of their molecular coupling with the dissolved API, steric hindrance and higher viscosity in
solution [14,15].
Despite the extensive in-depth studies carried out in ASDs, commercialization of ASDs is still
very limited (approximately 30 marketed products since 1975) [9,16–18]. This situation may stem from
a range of problematic issues of ASDs, mainly including physical stability, downstream processing and
scale-up difficulties [19–21]. In 2017, microwave-induced in situ amorphization was firstly proposed by
Doreth et al. as a promising approach to tackling these problems [22]. This technique can be utilized to
circumvent the physical stability issue and simplify the problematic downstream processing of ASDs
by preparing a final dosage form containing the crystalline drug and subsequently “activating”, i.e.,
amorphizing, the drug on demand within its final dosage form prior to administration using household
microwave ovens under an optimized and well defined operation setting, including microwave
power and time. The aim of this review is to provide a systemic overview of the state-of-the-art of
microwave-induced in situ amorphization as a novel ASD preparation strategy as well as highlighting
current challenges of this technology.
2. Current Issues in the Development of ASDs
2.1. Stability Issues of ASDs
Among all the challenges faced by ASDs, the issue of physical stability during manufacture and
storage has attracted widespread attention, since recrystallization of the amorphous drug from the
ASDs will result in a considerable loss of the solubilizing effects of the ASDs. The main factors affecting
the physical stability of ASDs are discussed in the following sections.
2.1.1. Thermodynamic Factors on the Physical Stability of ASDs
The thermodynamic driving force for recrystallization of amorphous APIs derives from a tendency
of the amorphous system with high free energy and excess enthalpy and entropy to relax towards
a lower free energy [23]. It has been suggested that when the amorphous API and polymer are
completely miscible and the drug loading is equal to or below the saturation solubility of the
crystalline API in the polymer, the ASDs are physically stable with no thermodynamic driving force for
crystallization [24,25]. However, such a drug loading is often too low to satisfy the pharmaceutical dose
required [26]. When the drug loading exceeds the drug–polymer solubility limit, the system becomes
thermodynamically unstable, which carries the risk of amorphous–amorphous phase separation
and/or drug recrystallization during manufacture and storage of such ASD systems. Therefore, from
the thermodynamic perspective, polymers that offer high drug–polymer solubility are favored as
carrier candidates for generating stable ASDs. Some findings suggested that a strong drug–polymer
interaction could lead to a reduction in the Gibbs free energy and enthalpy of mixing, which increased
the drug–polymer miscibility/solubility [27]. Such intermolecular interaction was also reported to be
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a critical attribute to the increase of configurational entropy of API molecules, which promoted the
thermodynamic stability of ASDs by connecting the drug and the polymer as a single entity [28].
2.1.2. Kinetic Factors on the Physical Stability of ASDs
From the kinetic point of view, the molecular mobility of amorphous materials mainly results
from α-relaxation [24], i.e., the glass transition temperature (Tg), which is related to the crystallization
time and the crystallization rate of amorphous materials, respectively [25,26].
A key factor contributing to the physical stability of ASDs is their molecular mobility, which is
mainly represented by the primary (α-) relaxation [29], i.e., the general mobility change responsible
for the Tg. In order to slow down the molecular mobility of amorphous materials, a rule of thumb
is that the storage temperature of such materials should be 50 K lower than their Tg (Tg – 50 rule).
Since drugs usually show a low Tg, a large quantity of high Tg polymers needs to be included in the
formulation to considerably increase the Tg of the resultant ASD systems (known as anti-plasticizing
effect) for kinetic stability enhancement [8]. Again, the high polymer ratio in the formulation may
result in a low drug loading. Additionally, polymers with a high Tg may cause difficulties in processing.
For instance, the use of such high Tg polymers in hot melt extrusion (HME), one of the most popular
preparation methods for ASDs, usually requires the aid of plasticizers, which in turn will reduce the
systemic Tg [30,31]. Polymers that interact with APIs through hydrogen bonds and ionic interactions
have been shown to restrict the molecular mobility of ASD systems in addition to their contribution in
thermodynamic stability [11,32].
2.1.3. Environmental Factors Affecting the Physical Stability of ASDs
Environmental factors including temperature, humidity and mechanical stress are indirect
factors affecting ASDs stability thermodynamically and/or kinetically. As reported by Lin et al.,
when the environmental temperature was elevated, there could be orders of magnitude increases
in molecular mobility according to the Adam–Gibbs–Vogel equation [8], resulting in an accelerated
phase separation and recrystallization of ASDs. Regarding the ambient humidity, it can introduce
a certain amount of moisture to the hygroscopic ASD systems. Kinetically, moisture can lead to a
plasticizing effect (reducing the systemic Tg), thereby increasing overall molecular mobility and the
risk for recrystallization. Furthermore, the absorbed water has the potential to disrupt drug–polymer
interactions by competing with hydrophilic polymers to form hydrogen bonds with APIs [33]. It was
also implied in some studies that moisture uptake could reduce the drug–polymer solubility, and the
extent of such effects varied with different APIs [34,35].
ASDs can also be sensitive to mechanical stress, such as grinding, crushing, scratching or
compressing during the formulation process, which can facilitate the deformation-induced molecular
mobility in amorphous APIs and result in phase separation or crystallization [11,36]. For instance,
milling of ASD extrudates after HME was observed to destabilize supersaturated ASD systems
compared to ASDs below the saturation solubility in the polymer [37].
2.2. Downstream Processing Issues of ASDs
Downstream processing of ASDs, typically consisting of feeding, blending and tableting, can have
an impact on the physical stability of ASDs by influencing the environmental factors, as described
in Section 2.1.3, as well as the content uniformity of final products, as reviewed in detail by various
research groups [6,38]. The latter issue with content uniformity is mainly ascribed to the poor flow
properties of bulk ASD powders for further processing. In this regard, current studies tend to focus on
alternative manufacturing strategies such as electrospinning, HME-injection molding and an HME–3D
printing combination, but the application of such approaches is often limited by the poor scalability as
compared to traditional formulation lines [6,39].
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3. In situ Amorphization
3.1. The Pharmaceutical Significance of in situ Amorphization
With regard to the aforementioned difficulties in ASD development, it is worth highlighting
that, although various solutions were proposed to promote the stability of ASDs, conventional ASD
systems with low drug–polymer solubility (usually lower than the drug loading) may always face
potential phase separation and recrystallization risks during manufacture and storage [26]. Even for
thermodynamically stable ASD systems, environmental factors such as high humidity are likely to
affect the drug–polymer miscibility and hence decrease the drug solubility in the polymer. However,
if the APIs can exist in their stable crystalline form within their formulations during the manufacturing
process and storage and subsequently be amorphized “in situ” on demand prior to administration,
the physical stability of ASDs is in theory only required during a very short period from in situ
amorphization to administration. Hence, the application of the in situ amorphization approach can not
only circumvent the physical stability concerns of ASDs but also avoid additional intermediate ASD
preparation steps such as spray drying or HME as well as issues related to the downstream processing
of ASDs, particularly the poor flowability [40,41].
3.2. General Development of in situ Amorphization
As reviewed by Priemel et al. in 2016 [26], in situ amorphization was initially depicted as an
“unintended” spontaneous amorphization event taking place prior to or after the administration
of poorly soluble crystalline drugs without deliberate external energy input (see Table 1 for a
summary of the latest literature supplemented). Here, in situ amorphization occurred spontaneously
due to the exposure of formulations to certain inducements and could be divided into three main
amorphization pathways: (i) dissolution-mediated approaches (dissolution of the crystalline drug
into a polymeric matrix in the presence of moisture or methanol vapor); (ii) vaporization-mediated
approaches (adsorption of sublimated drug onto porous excipients); and (iii) in situ amorphization
during lipolysis (mimicking in vivo digestion) of lipid-based oral formulations. Among the three
pathways, dissolution-mediated in situ amorphization utilizing tablets as the final dosage form is
believed to be the most promising application for "intended" in situ amorphization, since it directly
applies a final dosage form (i.e., tablets) rather than intermediate products such as physically mixed
powders or the lipid-baseddrug delivery systems that have the potential issue of unintended partial
amorphous precipitation [42].
Despite the application prospects of the above mentioned in situ amorphization approaches, other
issues could also arise, such as insufficient degree of amorphization, drug degradation, insufficient
disintegration and, most importantly, the long timeframes required to obtain the desired in situ
amorphization effects with such approaches, which varied from hours to months (Table 1). In order to
accelerate the pace and improve the controllability of in situ amorphization, microwave irradiation,
a fast and easy-to-use technology, has recently caught attention [43–45]. Some initial attempts have
been made using microwaves to induce ASDs in situ on the basis of dissolution-mediated in situ
amorphization [22,46,47]. Hence, in the following sections, microwave-induced in situ amorphization
is reviewed in more detail.
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Table 1. The applications of non-microwave induced in situ amorphization in oral drug delivery.
Category API Upstream Processes Inducements of in situ Amorphization Post-AmorphizationDosage Form Impact of in situ Amorphization Ref.
Dissolution-mediated
in situ amorphization
Paracetamol, ibuprofen (IBU),
ketoprofen and naproxen
Mixing (API–polyethylene oxide),
compaction
Moisture uptake during storage (room
temperature (RT), 94% relative humidity
(RH)) of compacts for 3–4 weeks
Compact NA [26]
IBU Dry mixing for 3 h (API–hydroxypropylmethyl cellulose)
Methanol or water spray followed by
milling for 1–3 h; storage in saturated
methanol vapor for 16 h; saturated
methanol vapor followed by milling
for 16 h
Powder NA [26]
Indomethacin (IND) Dry mixing for 3 h (API–hydroxypropylmethyl cellulose)
Saturated methanol vapor followed by
milling for 16 h
IND Mixing (API–Eudragit® E), compaction
Immersion in pH 6.8 phosphate buffer
for 1–3 h at 37 ◦C Compact
Improved dissolution behavior
when the swelling degree was high [26]
Naproxen, IBU Mixing (API–Eudragit® E), compaction
Immersion in 50 mL purified water
for 1 h Compact Improved dissolution behavior [48]
IND Mixing (API–L-arginine), blending,compaction, coating (Kollicoat® Protect)
Moisture uptake during storage (RT, 75%
RH), not completely amorphized even
after 91 days
Coated compact Good mechanical stability; improvedbioavailability [40]
IND Mixing (API–L-arginine)
Moisture uptake during storage (RT, 75%
RH), not completely amorphized even
after 101 days
Powder Chemical degradation [49]
Furosemide, IND Mixing (API–L-arginine), blending,compaction, coating (Eudragit® L)
Immersion in 0.1 M HCl for 10–30 min at
37 ◦C (co-amorphization);
recrystallization after longer
immersion times
Coated compact
L-arginine induced chemical
degradation of IND (prevented by
adding citric acid but at the expense
of amorphization)
[50]
Carvedilol Mixing (API–L-aspartic acid), blending,compaction, coating (Eudragit® L)
Immersion in 0.1 M HCl for 45 min at
37 ◦C (co-amorphization) Coated compact
Insufficient disintegration and poor
drug release [51]
Vapor-mediated in
situ amorphization
Aspirin, phenacetin Mixing (API–magnesium aluminumsilicate/activate carbon)
Storage at 25 ◦C with silica gel for 1–2
week; storage at 40 ◦C with reduced
pressure for 2–8 h
Powder NA [26]
IBU Mixing (API–silica)
Storage at 40 ◦C, 0% RH for 4–5 weeks;
hydrophilic, small pore diameter silica
was preferred Powder
Potential instabilities due to drug
molecules migration and subsequent
interaction with excipients
[26]
Diflunisal Mixing (API–silica) Storage at 80 ◦C, 0% RH for 2–3 weeks
In situ amorphization
during lipolysis
Cinnarizine, halofantrine and
simvastatin
Preparing the self-microemulsifying
drug delivery systems (SMEDDS) or the
self-nanoemulsifying drug delivery
systems (SNEDDS)
Immersion in lipolysis medium for
approx. 1 h SMEDDS or SNEDDS
Unintended partial amorphous
precipitation. Lack of correlation of
in vitro precipitation to the in vivo
performance
[26]
NA: not available.
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4. Microwave-Induced in situ Amorphization
4.1. Microwave Heating
Microwaves are electromagnetic waves with high frequencies (0.3–300 GHz) and wavelengths in the
cm range, i.e., 1–0.001 m, which have been widely used in the fields of communication, radar, industry,
scientific research, medicine and domestic life [52]. Microwave heating systems are usually restricted
within the industrial, scientific and medical (ISM) frequency bands, using certain license-free frequencies
designated by the International Telecommunication Unit (ITU) with international agreements [53].
Among them, the most commonly used frequency for commercial and domestic uses in most countries
is 2.45 GHz with a wavelength of 0.122 m and a penetration depth of 0.014 m in water at 25 ◦C [54,55].
In the pharmaceutical industry, microwave heating is mainly applied to modify the
physicochemical characteristics and drug delivery performances of dosage forms (e.g., SDs, orally
disintegrating tablets, film coating preparations and gel beads) through microwave-assisted drying,
curing, fusion, sintering, crosslinking etc. [56,57]. It is well known that in conventional heat treatments,
energy is transferred via heat convection, conduction and radiation from the surface to the body of a
material. In contrast, in microwave heating, energy is transferred directly to both the surface and the
body of a material through molecular interactions in the electromagnetic field, with energy converted
directly from the electromagnetic energy into heat, which can be primarily explained through the
dipolar polarization mechanism [58]. To be able to absorb microwaves, a material needs to have suitable
dielectric properties, i.e., a molecule that exhibits a sufficiently strong dipole moment and is sufficiently
small or flexible to rotate within the material structure, such as water [59]. Heating is achieved by
coupling microwave radiation to the dipole moment of the molecule and exciting (hindered) rotational
motions of these molecules within the material [60]. Specifically, when a direct current electric field is
applied, the dipoles of the material will change from a disordered and irregular state to a state with
specific orientation and generate potential energy. If the direction of the electric field is changed rapidly
and alternately (with alternating current applied), dipoles will oscillate rapidly in order to track the
electric field. The ease of the movement of dipoles in the field depends on the viscosity and the mobility
of the electron clouds. Due to the molecular thermal motions and the intermolecular interactions, the
regular oscillation of dipoles can be disturbed or hindered, resulting in a friction-like effect that enables
the molecules to obtain energy and release it in the form of heat. Consequently, the temperature of the
material increases, which is known as the specific effects of microwave [61]. The above mechanism
endows microwave heating distinct characteristics from conventional heating, such as rapid volumetric
heating, selective heating (high dielectric substances are favored), low energy consumption, easy
operation and low preparation costs [44,62]. The conversion of the microwave energy to heat can be
described with the following formula (Equation (1)) according to the electromagnetic field theory:
P = 2pi fε0ε
′′
r E
2 (1)
where P is the microwave power dissipation (W·m–3); f is the frequency and E is the intensity of the
electric field; ε0 is the permittivity of free space (a vacuum), whose value is 8.854 × 10−12 F·m−1; εr”
is the imaginary part of the complex dielectric permittivity, which refers to the dielectric loss and
represents a major parameter related to the microwave heating [63].
The formula suggests that a high frequency and a strong intensity of the applied electric field can
contribute to more heat generation (high P value), and materials with high dielectric loss can be more
efficiently heated up in the microwave field.
4.2. Microwave Heating for Bulk Preparation of Amorphous Glass Solutions
It is not surprising that microwaves have also been introduced for the preparation of ASDs.
However, unlike water, polymers and drug molecules are poor microwave absorbers [64,65] and hence
do not heat up sufficiently on their own in order to form an ASD. As a consequence the preparative
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methods described in the literature typically take advantage of the following effects: i) convective
heating, i.e., a microwave absorbing reactor or sample holder is heated up and this heat is then
transferred to the sample indirectly [43,44,66–75], and ii) addition of a microwave absorbing solvent
to the formulation in excess and subsequent solvent evaporation from a drug–polymer solution [76]
or solvent slurry [77,78]. In both cases, microwave heating is merely replacing traditional heating
methods and hence, adds little specific benefits compared to preparative methods such as hot melt
extrusion and spray drying. In addition, the prepared ASDs require further processing and handling
into a pharmaceutical dosage form, such as a tablet, and most importantly they face the same stability
issues as conventionally prepared ASDs upon storage.
Microwave heating has been utilized as an alternative fusion-based (convective heating) ASD
preparation method since 2008, when it was used to induce amorphization of IBU in the hydrophilic
carriers including polyvinylpyrrolidone/vinyl acetate 64 (PVP/VA 64) and HP-β-cyclodextrin
(β-CD) [44]. The authors found that physically mixed IBU:PVP/VA 64 1:1 (w/w) powders could
turn partially amorphous when microwaved for 6 min at 600 W. A similar system composed of
IBU:β-CD at a 1:2 molar ratio reached 100% amorphicity after microwaving at 600 W for 15 min.
In dissolution tests, microwave processed powder systems with high amorphicity incorporating
either carrier showed enhanced dissolution behavior in water compared to IBU, IBU-carrier physical
mixtures and mixtures of separately microwaved IBU and carriers. Since then, several studies showed
the viability of using microwaves to prepare bulk ASD powders, as shown in Table 2. In general,
the primary process of the microwave-induced amorphization involves three steps:
(i) Preparing the physically mixed API-carrier powders. It is worth noting that low Tg carriers
(polymers, surfactants or the combination of both) have frequently been used (Table 2) as they
can possibly be molten or softened at relatively low temperatures;
(ii) Treating the physically mixed loose powders with continuous or intermittent microwaves to
induce amorphization; and
(iii) Cooling, pulverizing and sieving to get the final bulk ASD powders.
With the application of microwave heating in ASDs, an evident advantage appears over most of
the other fusion-based methods, where relatively long exposure under high temperature is required to
melt the drug and carrier, which may lead to degradation of some thermally unstable components [79].
In the case of microwave heating, the processing time is usually less than 15 min, greatly reducing the
exposure time and potentially protecting the components from degradation [80,81].
Most of the studies summarized in Table 2 used microwave absorbing reactors or sample holders,
i.e., materials that are heated during microwave processing, such as beakers and crucibles, which in
turn heat up the sample through convective heating. Hence, it is likely that the amorphization of the
drug follows the same conductive heating mechanism as that of the conventional fusion-based ASD
preparation methods. This means that the effect of conductive heating on drug amorphization cannot
be completely excluded when analyzing the mechanisms of microwave-induced amorphization, and
the aforementioned benefits of this technology may not be fully ascribed to microwave heating within
the sample itself. Therefore, the use of microwave transparent sample holders, such as polypropylene
(PP) and polytetrafluoroethylene (PTFE) [22,64,82], will help to better understand the role of microwave
irradiation in microwave-induced ASD preparation.
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Table 2. Summary of publications on the application of microwave heating in the preparation of bulk amorphous solid dispersion (ASD) powders.
Year Microwave Instrument Power (W) ProcessingTime (min)
Microwave Absorbing
Sample Holder API Carrier Cooling Method
Drug
Released % Ref.
2008 CE297DN, Samsung 600 6 Beaker IBU β-CD; PVP/VA 64 (did notachieve fully amorphous) NA 90 (2 min) [44]
2009 CE297DN, Samsung 600 15; 9 Beaker Nimesulide Gelucire® 50/13; Poloxamer 188 NA
>90 (16 min);
>90 (70 s) [66]
2010 CATA-2R, Catalyst Systems,Pune, India 590 3; 4; 5; 6 Beaker
Atorvastatin
calcium PEG6000 RT
52; 57; 61; 64
(120 min) [67]
2010 CE297DN-Samsung, Surrey,England 600 10 Beaker Itraconazole
D-α-tocopheryl polyethylene
glycol 1000 succinate RT >90 (2 min) [68]
2011 Modified domesticmicrowave oven
Variable
power Around 30 Crucible IBU Stearic acid; PVP 40 RT >60 (20 min) [43]
2012 CATA-2R, Catalyst Systems,Pune, India 600 3; 4; 5; 6 Glass beaker Repaglinide Poloxamer 188 NA
68; 73; 80; 82
(60 min) [69]
2013 CATA-2R, Catalyst Systems,Pune, India 590 3; 4; 5; 6 Beaker Raloxifene HPMC E5 LV RT
50; 57; 60; 65
(120 min) [70]
2013 CATA-2R, Catalyst Systems,Pune, India 600 5 Glass beaker Repaglinide PEG 6000 NA 86 (120 min) [71]
2013 Catalyst systems, Pune, India 440 NA NA Glipizide PEG 4000 Ice bath NA [83]
2014 CATA-2R, Catalyst Systems,Pune, India 560 NA Glass beaker
Candesartan
Cilexetil PEG 6000; HPMC E5 NA > 90 (5 min) [72]
2016 P70F23P-G5(SO), Glanze 550 10 Crucible IBU Soluplus®
Liquid nitrogen
(−196 ◦C) NA [73]
2017 ME0113M1, Samsung 900 Different timeof interval Glass beaker
Mefenamic
acid;
flufenamic
acid
Pluronic F127®; Eudragit EPO®;
PEG 4000; Gelucire 50/13
RT, with one exception
under −80 ◦C
80 (40 min) for
optimum
prescriptions
[74]
2019 P70F23P-G5(SO), Galz,Guangzhou, China 700 2 Porcelain dish
IND;
fenofibrate Soluplus
® Liquid nitrogen at−196 ◦C NA [84]
2020 ME0113M1, Samsung 500 NA Glass beaker Luteolin PEG 4000 NA >60 (20 min) [75]
NA: not available.
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Microwave heating has also been applied to process drug–polymer solutions and slurries using
high-loss polar solvents for the fabrication of bulk ASD powders. For example, water has been used
in API–hypromellose acetate succinate (HPMCAS) and API–HPMCAS–urea physical mixtures to
prepare homogeneous slurries, which heated up and evaporated during microwaving to induce full
amorphization of the API [77,78]. In another study, Radacsi et al. prepared a niflumic acid–PVP–ethanol
solution, which was subjected to a well-designed microwave-assisted evaporation setup with a constant
power of 300 W [76], and a completely amorphous ASD was formed, showing a significantly enhanced
dissolution performance relative to crystalline niflumic acid.
4.3. Microwave-Induced In Situ Amorphization within the Final Dosage Form
As outlined above, microwave heating was demonstrated to be a feasible alternative in the
manufacture of bulk ASDs. However, like traditional ASD preparation methods, fabrication of
intermediate loose ASD powders using microwave heating still cannot overcome the physical stability
and downstream processing issues of ASDs. The true potential of using microwaves to induce
amorphization lies in its applicability on the final dosage form. In other words, if microwave-induced
amorphization can occur within the final dosage form, i.e., in situ, the consistent physical stability and
downstream processing issues of ASDs can be avoided while amorphous drugs are formed to present
enhanced dissolution performances. This novel concept was introduced by Doreth et al. in 2017 as an
in situ amorphization process where a given drug is amorphized via microwave irradiation within
its final dosage form [22]. Since it is still a new approach, there are currently only few publications
available on microwave-induced in situ amorphization (all using PP as the microwave transparent
sample holder), which are summarized in the following four subsections.
4.3.1. The Role of Microwave Energy Input and Storage Humidity
In the first proof of concept study by Doreth et al. in 2017, a significant impact of microwave
energy input and storage humidity of final dosage forms on the degree of microwave-induced in situ
amorphization was found in the IND:PVP systems (Figure 1) [22]. In this study, compacts containing a
powder mixture of crystalline IND, the polymer PVP K12 (drug:polymer 1:2 (w/w)) along with a glidant
and a lubricant (colloidal silicon dioxide and magnesium stearate, respectively) were prepared and
subjected to microwave irradiation. It was initially found that plain compacts without further treatment
did not amorphize due to the poor electro-chemical coupling of the drug and polymer, and hence,
the poor response when subjected to the microwaves. Because of this, the authors introduced different
amounts of absorbed water by conditioning the compacts at different RH (32, 43 and 54% RH) for at
least two weeks. The absorbed water then acted as the microwave absorbing entity in the compacts.
The study also made use of different microwave energy inputs based on various combinations of the
irradiation power (300, 600 and 1000 W) and the processing times (50, 90, 150 and 300 s). It was observed
that the degree of amorphization of IND increased as the amount of absorbed water in the compacts
and microwave energy increased. The highest IND amorphicity around 80% was achieved with
compacts containing the highest amount of water (9.8% (w/w)) while applying the highest energy input
(90 kJ). The authors suggested that a complete amorphization was not achieved upon microwaving,
because the absorbed moisture had evaporated too fast from the surface of the compacts, resulting in a
surface with low water content, which did not sufficiently absorb the microwave energy anymore for
the amorphization process. Hence, a shell layer containing the crystalline drug was formed, whereas
the core of the compacts could be amorphized during microwaving. Overall, the study showed that in
situ amorphization using microwaves can be achieved in the presence of a microwave absorbing entity
in the compacts, i.e., absorbed water.
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4.3.2. The Role of the Molecular Weight of Polymeric Carriers
In a follow-up study by Doreth et al. (2018), the authors investigated the impact of the molecular
weight of the polymer PVP on the degree of amorphization upon microw ving [46]. Specifically,
PVP K12, K17 and K25 with diff rent m lecular weights (2000–3000 g·mol−1, 7000–11,000 g·mol−1
and 28,000–34,000 g·mol−1, respectively) were studied as the mod l polymeric carriers. Compacts
containing the crystalline drug and the different PVP grades at a ratio of 1:2 (w/w) were initially
conditioned at 54% RH and subsequ ntly subjected to th microwave energies of 90 kJ and 180 kJ. It was
found that PVPs with different molec lar weights exhibit similar hygroscopicity r flected by the
similar moisture ptake (approx. 10% (w/w)) in all comp cts after torage. However, the m rpholog
of the compacts was different when using different PVP grades. As illustrated in Figure 2, the c mpacts
containing PVP K12 presented the greatest reductio in porosity after the microwaving tre tment
as compared to those containi g PVP K17 and PVP K25. It was sugg sted that this morphological
change might have l d to less oisture evaporation, which explained the lowest moisture loss after
microwaving observed wit IND:PVP K12 compacts among the three formulations. Hence, the highest
drug amorphicity was found in IND:PVP K12 compacts, namely 31% with 90 kJ energy input and
58% with 180 kJ en rgy input, whereas com acts containing PVP K17 and K25 showed almost no
crystallinity decrease after exposure to microwave irradiation with either energy inputs. Moreover, the
low porosity of the microwaved IND:PVP K12 ompacts can be associated with the initi l delayed
release of such compacts in th dissolution assessment, which is further discussed in Section 4.3.4.
It was also suggested that th superiority of PVP K12 in promoting amorphicity could be explained
by fact that PVP K12 was the only polymer in this study possessing a Tg below RT after storage
due to the plasticizing effect of water, implying the transformation from glassy to supercooled liquid
state occurred with an increased chain flexibility. The enhanced chain flexibility then led to an
increase in the molecular mobility of water molecules within the conditioned IND:PVP K12 compacts,
which facilitated the molecular friction and heat generation upon microwaving. Moreover, further
investigation demonstrated that such a plasticizing effect of water was advantageous not only in
microwave-induced in situ amorphization, but also when compacts were exposed to convective
heating [85].
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4.3.3. Dissolution of the Drug into the Polymeric Carrier
In a recent study by Edinger et al. (2018) the success of microwave-induced in situ amorphization
was suggested to be related with the dissolution of the drug into the polymer upon microwaving, where
the polymer acted as the "solvent" for the crystalline drug [47]. Here, compacts containing physically
mixed celecoxib (CCX), PVP K25 at drug loadings of 10, 20, 30, 40 and 50% (w/w) together with
0.5% (w/w) magnesium stearate were compressed, stored at RT, 75% RH for 4 weeks and subjected to
microwave irradiation at 1000 W in 60 s intervals for 10 min. Microwave-induced in situ amorphization
was mostly observed to take place in the first 4–5 min of microwave processing, and higher degrees of
amorphization were obtained for lower drug loadings. Nevertheless, full amorphization could not be
achieved even at 10% (w/w) drug loading. Since the drug needs to dissolve into the polymer network
during microwaving, the assumption proposed in this study was that the lack of full amorphization
might have be due to the large particl size of the drug crystal , which resulted in the formation of
saturated drug–polym r diffusion layer that indered the further dissolution of the drug into the
polymer. I addition, the likelihood of forming drug particle clusters creases with the increase in
drug loading, leading to nsuffici nt direct contact between he drug nd polymer particles and further
hindering amorphization process.
Therefore, in a subsequent study by Hempel et al. in 2 20, the particle size of drug and polymer
was reduc d to improve drug–p lymer c tact and enhance the issolution of the crystalline drug into
the polym r [86]. Using this approach, it was possible for the first time to obtain a full amorphization
of th drug CCX. The starting materials, CCX and PVP (Kollidon® 12PF), ere prepared i two particl
size fractions, either small (<71 µm, ball-milled an sieved) o large (>71 µm, ieved), and compacts
containing CCX:PVP:magnesium stearate at a 30:69.5:0.5 ratio (w/w) were stored under the same
con ition as reported by Edinger et al. [47]. Micr wave parameters were set at 1000 W in 60 s intervals
for 10 min or continuously for 10 min. It is teworth that the 100% amorphic ty was achieved
only in tablets with small CCX and PVP particles subjected to continuous exposure o m crowaves,
which was 76% highe than the amorphicity of the same tablets under int rval exposure and approx.
30–75% higher than that of tablets with other particle size combinations under contin ous microwave
exposure. The patterns of microwave exposure, interval or continuous, was suggested to have an
fluence on the total exposure ime of the ompacts above th Tg of the polymer and the emerging
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ASD. Continuous microwaving resulted in a longer total effective exposure time above the Tg of the
system and, hence, led to an overall longer time for the crystalline drug to dissolve into the polymer.
On the basis of the above findings, the authors proposed that both the particle size of components and
effective microwave exposure time contributed to the amorphization by improving the dissolution of
the drug in the polymer. However, the former had a more significant influence on microwave-induced
in situ amorphization than the latter, which was demonstrated by the fact that compacts consisting of
components with large particle sizes could only achieve half the amorphicity of the small particle size
group despite an additional 300 s of effective microwave exposure (illustrated in Figure 3).
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respectively. Mean ± SD (n = 3). The dashed lines indicate different Tgs. (Reproduced from [86]).
The importance of the dissolution of drug in polymer was also addressed by Hempel et al. in a
comparative study of microwave heati g and convective heating to induce in situ amorphization [85].
Two experimental setups were applied in the study, i cluding a microwave-induced method identical to
the one that successfully led to 100% CCX amorphicity, as previo sly described [86], and a omparable
conve tion-induced method that imitated the setup of the former. Results showed that for conditioned
(RT and 75% RH for 2 weeks) CCX:PVP tabl ts, the drug amorphicity in the convection heating group
failed to re ch 100% relative to the full ASD obtained in the microwave h ating group even when
applying 3-fold long r heating times. This was primarily due to the fact that the convect on heating
group exhibit d a delayed temperature rofile as c mpared to the microwave eating g oup arising
from their different heating mec anisms, which resul in a delayed dissolution pr cess of CCX into
he PVP and ultimately an incomplete in situ amorph zation.
4.3.4. Performance of Microwave-Induced ASDs Activated in situ
Doreth et al., in 2017, found that no microwave-induced drug degradation was detected in the
IND:PVP system after all processing treatments [22]. Furthermore, it was found that the intrinsic
dissolution rate of the microwaved tablets with the highest amorphicity (80%) was 6.3-fold higher than
that of the physical mixture containing crystalline IND and PVP. More importantly, even though no full
amorphization was achieved, the dissolution rate was comparable to that of the quench-cooled fully
amorphous samples. In another publication in 2018, Doreth et al. evaluated the in vitro dissolution of
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microwaved compacts under non-sink conditions at pH 6.8 [46]. As shown in Figure 4, microwaved
IND:PVP K12 compacts exhibited a slower initial release of IND compared to other formulations, which
was possibly related to the low porosity and high hardness as well as a lack of disintegration that took
approx. 4 h in comparison to the high porosity, low hardness and approx. 10 min disintegration time
of microwaved IND:PVP K17 and IND:PVP K25 compacts. Such a phenomenon has been previously
described in relation to the "soft and waxy nature" of ASDs by Serajuddin et al. [87], where polymeric
carriers are known to be strong binders within tablets and can reduce the porosity of tablets when
they are softened, molten or plasticized during compression. Nevertheless, microwaved IND:PVP
K12 compacts showed the highest extent of drug release among all formulations studied after 3 h
mainly due to the highest IND amorphicity, as previously stated in Section 4.3.2. To alleviate this issue,
disintegrants or porogens potentially need to be added to the formulation in future investigations.
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5. Challenges and Future Perspectives
icro ave-induced in situ a orphization is a very pro ising and novel ethod to prepare
S s in final formulations. However, to date there have been only a limited number of investigations
addressing the pharmaceutical applications of such a new technology where many facets still
require further investigations, including the underlying mechanisms and influencing factors of
microwave-induced in situ amorphization (the main focus of current publications); the chemical
stability of materials prior to, during and post processing; the selection criteria of excipients; the
practicality of the dosage form after processing; the reproducibility of the microwaved formulations
and a feasible control unit/indicator that allows the pharmacist and patient to identify whether a
successful amorphization has been achieved after processing; as well as the clinical application of
this technology.
ith respect to the che ical stability of the drug, there is a risk of drug degradation during
icro ave processing due to the applied icro ave energy on the sa ple. o ever, even prior to
microwaving, the presence of absorbed water, which is a prerequisite to enable in situ amorphization
by microwave irradiation, can potentially lead to hydrolysis and drug degradation. It should be noted
that the reason why no degradation of IND was detected in the study by Doreth et al. might be due to
the short storage period (RT and 54% RH for two weeks) prior to microwaving at 1000 W for 90 s [22].
Considering the large amount of absorbed water (approx. 10%) present in such systems, it is likely
that long term storage may have a significant impact on the chemical stability profile. Therefore, more
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systematic investigations into the drug degradation during storage and microwave processing need to
be conducted.
Up to date, only a limited number of polymers have been explored in this field with a main
focus on PVP K12. In order to study a broader applicability of the concept, it is critical to study
other polymeric and non-polymeric carriers. In this context, the type of carrier material may have an
impact on the hardness and disintegration properties of tablets in addition to the drug amorphicity
upon microwaving. For example, even though fully amorphous systems could be obtained with PVP
K12, there are still some challenges with respect to the dosage form, its preparation and processing:
(i) form stability issues of the compacts investigated so far, which deformed primarily due to water
evaporation and became highly dense with low porosity after microwaving [22,46,47]; (ii) the tablet size
and compaction pressure during production presumably have impacts on the amorphization kinetics;
(iii) APIs with different glass forming abilities might show different performance in microwave-induced
in situ amorphization; and (iv) the influence of the precise position of the tablets in microwave ovens on
microwave-induced in situ amorphization. All these issues require more in-depth studies in the future.
Regarding a potential future clinical application of this technology, it is critical that the quality
of microwave-able dosage forms is ensured by health care professionals, such as pharmacists, before
distributing the medicine to the patients. On one hand, the manufacturing and packaging of the
products should be carefully designed (e.g., using moisture substitutes or encapsulation) for microwave
processing in order to avoid changes in the optical appearance of the dosage forms whilst providing
full amorphization with the desired dissolution performance. On the other hand, a standard operation
procedure, including the microwave setup and processing, should be developed to guarantee good
reproducibility of the microwaved formulations. In addition to in vitro dissolution studies that were
investigated in the previous studies, in vivo drug release and pharmacokinetic properties of the
microwave-induced ASDs should also be investigated with a final view to further translating such a
promising technology.
6. Conclusions
This review has provided an overview of the current stage and future perspectives of
microwave-induced in situ amorphization. In situ amorphization has previously been observed,
mostly unintentionally, during manufacturing, storage, dissolution and lipolysis; however, when using
microwave irradiation, one can use it intentionally and on demand. Even though the generation of
microwave-induced ASDs is still a fairly new technology with current challenges, it has significant
potential of providing a novel means of preparing ASDs and at the same time circumventing stability
or downstreaming issues associated with the current manufacturing routine for ASDs.
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